-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Liver Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CM-101 in Liver Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Liver Fibrosis Drug Details: CM-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CM-101 in Primary Sclerosing Cholangitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Primary Sclerosing Cholangitis Drug Details: CM-101 is under development...
-
Product Insights
NewNet Present Value Model: Purple Biotech Ltd’s CM-24
Empower your strategies with our Net Present Value Model: Purple Biotech Ltd's CM-24 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-24 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-24 in Pancreatic Ductal Adenocarcinoma Drug Details: CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Systemic Sclerosis (Scleroderma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Systemic Sclerosis (Scleroderma) Drug Details: CM-101 is under development for the treatment of non-alcoholic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: CM-101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval Analysis for Familial Amyloid Cardiomyopathy
Overview How likely is it that the drugs in Familial Amyloid Cardiomyopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Amyloid Cardiomyopathy Overview Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid...
-
Company Insights
Innovation and Patenting activity of CM Hospitalar SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CM Hospitalar SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of CMS Energy Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CMS Energy Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy Drug Details: BBP-265 (AG-10)...